Figure 2
Forest plot showing the incidence of heart failure with SGLT-2 inhibitors compared with placebo in patients with and without chronic kidney disease (CKD). Results are stratified by CKD status. Data are presented as risk ratios (RR) with 95% confidence intervals (95% CI). A lower incidence of heart failure is identified with SGLT-2 inhibitors compared with placebo in patients with and without CKD (p for interaction 0.08 suggesting a stronger treatment effect with SGLT-2 inhibitors in the subgroup of patients with CKD). A random effects model is used.
